These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34744456)

  • 61. ASRGL1 Correlates With Immune Cell Infiltration in Hepatocellular Carcinoma and Can Serve as a Prognostic Biomarker.
    Xue C; Gao P; Cui X; Zhang X; Lei J; Li R; Zhu C; Qin X
    Front Oncol; 2021; 11():680070. PubMed ID: 34249720
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Potential Role of NEU1 in Hepatocellular Carcinoma: A Study Based on Comprehensive Bioinformatical Analysis.
    Wu Z; He L; Yang L; Fang X; Peng L
    Front Mol Biosci; 2021; 8():651525. PubMed ID: 34513919
    [No Abstract]   [Full Text] [Related]  

  • 63. Decreased Expression of ZWINT is Associated With Poor Prognosis in Patients With HCC After Surgery.
    Yang XY; Wu B; Ma SL; Yin L; Wu MC; Li AJ
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794190. PubMed ID: 30198401
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of hub genes and biological pathways in hepatocellular carcinoma by integrated bioinformatics analysis.
    Zhao Q; Zhang Y; Shao S; Sun Y; Lin Z
    PeerJ; 2021; 9():e10594. PubMed ID: 33552715
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma.
    Wang Z; Zheng W; Chen Z; Wu S; Chang H; Cai M; Cai H
    Front Oncol; 2022; 12():1055376. PubMed ID: 36531056
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Downregulation of GNA14 in hepatocellular carcinoma indicates an unfavorable prognosis.
    Yu T; Lu S; Xie W
    Oncol Lett; 2020 Jul; 20(1):165-172. PubMed ID: 32565944
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Systemic Expression Analysis Reveals Prognostic Significance of WIPI3 in Hepatocellular Carcinoma.
    Liang TT; Shao Q; Deng ZC; Wang T; Kang QZ
    Front Genet; 2020; 11():847. PubMed ID: 32973867
    [TBL] [Abstract][Full Text] [Related]  

  • 68. RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma.
    Peng H; Zhu E; Wang J; Du X; Wang C; Yang M; Zhang Y
    Front Pharmacol; 2022; 13():989655. PubMed ID: 36120364
    [No Abstract]   [Full Text] [Related]  

  • 69. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases.
    Zhang P; Feng J; Wu X; Chu W; Zhang Y; Li P
    Pathol Oncol Res; 2021; 27():588532. PubMed ID: 34257537
    [No Abstract]   [Full Text] [Related]  

  • 70. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
    Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
    World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients.
    Lu T; Li C; Xiang C; Gong Y; Peng W; Chen C
    Biomed Res Int; 2022; 2022():7823191. PubMed ID: 35313629
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Integrative bioinformatics and experimental analysis revealed TEAD as novel prognostic target for hepatocellular carcinoma and its roles in ferroptosis regulation.
    Ren X; Wang X; Yan Y; Chen X; Cai Y; Liang Q; Peng B; Xu Z; He Q; Kang F; Li J; Zhang W; Hong Q; Peng J; Xiao M
    Aging (Albany NY); 2022 Jan; 14(2):961-974. PubMed ID: 35077390
    [TBL] [Abstract][Full Text] [Related]  

  • 73. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.
    Tang M; Liao M; Ai X; He G
    Front Med (Lausanne); 2021; 8():773724. PubMed ID: 35372372
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis.
    Yang WX; Pan YY; You CG
    Biomed Res Int; 2019; 2019():1245072. PubMed ID: 31737652
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma.
    Wang Z; Wen P; Hu B; Cao S; Shi X; Guo W; Zhang S
    Cancer Cell Int; 2021 Oct; 21(1):586. PubMed ID: 34717619
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
    Yu B; Ding Y; Liao X; Wang C; Wang B; Chen X
    Dig Dis Sci; 2019 Oct; 64(10):2878-2892. PubMed ID: 30949905
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nine hub genes related to the prognosis of HBV-positive hepatocellular carcinoma identified by protein interaction analysis.
    Xie W; Wang B; Wang X; Hou D; Su H; Huang H
    Ann Transl Med; 2020 Apr; 8(7):478. PubMed ID: 32395522
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
    Cai C; Zhang Y; Hu X; Hu W; Yang S; Qiu H; Chu T
    Front Oncol; 2021; 11():721644. PubMed ID: 34631549
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Systematic summarization of the expression profiles and prognostic roles of the dishevelled gene family in hepatocellular carcinoma.
    Mei J; Yang X; Xia D; Zhou W; Gu D; Wang H; Liu C
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1384. PubMed ID: 32588988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.